# Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

> **NCT07468136** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 33 (estimated)

## Conditions studied

- Anaplastic Oligodendroglioma
- Astrocytoma, IDH-Mutant, Grade 3
- Astrocytoma, IDH-Mutant, Grade 4
- Diffuse Astrocytoma
- Glioblastoma, IDH-Wildtype
- Malignant Glioma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Eflornithine
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Retifanlimab
- **PROCEDURE:** Tumor Resection

## Key facts

- **NCT ID:** NCT07468136
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2030-10-25
- **Final completion:** 2030-10-25
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468136, "Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07468136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*